Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction
© Shelton and Harris; licensee BioMed Central Ltd. 2008
Received: 08 January 2008
Accepted: 11 February 2008
Published: 11 February 2008
The hepatitis C virus (HCV) non-structural 5A protein (NS5A) contains a highly conserved C-terminal polyproline motif with the consensus sequence Pro-X-X-Pro-X-Arg that is able to interact with the Src-homology 3 (SH3) domains of a variety of cellular proteins.
To understand this interaction in more detail we have expressed two N-terminally truncated forms of NS5A in E. coli and examined their interactions with the SH3 domain of the Src-family tyrosine kinase, Fyn. Surface plasmon resonance analysis revealed that NS5A binds to the Fyn SH3 domain with what can be considered a high affinity SH3 domain-ligand interaction (629 nM), and this binding did not require the presence of domain I of NS5A (amino acid residues 32–250). Mutagenic analysis of the Fyn SH3 domain demonstrated the requirement for an acidic cluster at the C-terminus of the RT-Src loop of the SH3 domain, as well as several highly conserved residues previously shown to participate in SH3 domain peptide binding.
We conclude that the NS5A:Fyn SH3 domain interaction occurs via a canonical SH3 domain binding site and the high affinity of the interaction suggests that NS5A would be able to compete with cognate Fyn ligands within the infected cell.
Hepatitis C virus is an enveloped RNA virus that is estimated to infect 2% of the global population, 123 million individuals . The virus has a positive sense RNA genome of 9.5 kb that comprises a single open reading frame encoding a ~3000 residue polyprotein, flanked by 5' and 3' untranslated regions. The polyprotein is cleaved into 10 individual polypeptides by a combination of host-cell and viral proteases, the N-terminal one-third of the polyprotein produces the four structural proteins (Core, E1, E2 and p7), whereas the C-terminal two-thirds comprises the six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B). Use of a sub-genomic replicon system has demonstrated that five of these (NS3-NS5B) are necessary and sufficient to replicate an RNA molecule containing the 5' and 3' untranslated regions of the viral genome. However, apart from the RNA-dependent RNA polymerase (NS5B), the precise details of the roles of each of the non-structural proteins in the process of RNA replication remain undefined.
A number of other viral proteins interact with host cell SH3 domains – the best characterised of these is the HIV-1 Nef protein. The interaction between Nef and the SH3 domain of the Src-family kinase, Hck, is reported as one of the strongest interactions between an SH3 domain and its ligand (KD = 250 nM) , results in activation of the kinase and has been shown to be required for viral pathogenesis in vivo . The affinity of a Nef derived PxxPxR-containing peptide for the Hck SH3 domain was much lower than that of the intact protein (KD = 91 μM), suggesting that the interaction between Nef and the Hck SH3 domain involved additional intermolecular interactions. We were therefore interested to determine the molecular details of the NS5A:SH3 domain interaction. As an initial approach to this question we used the crystal structure of Nef complexed with a mutated form of the Fyn tyrosine kinase SH3 domain (R96I)  as the basis for a molecular modelling study to predict the residues involved in the interaction between the NS5A PP2.2 motif and the Fyn SH3 domain . The results of this study predicted that NS5A would interact with the SH3 domain in a very similar fashion to Nef, and the work presented here was designed to evaluate this prediction using both surface plasmon resonance and mutagenesis of the Fyn SH3 domain. The data confirm the predictions, and furthermore show that NS5A interacts with the Fyn SH3 domain with a similar affinity to that exhibited by the Nef:SH3 domain interaction. We conclude that NS5A binds to SH3 domains with high affinity, and such interactions could occur in the context of an HCV infected cell.
Results and discussion
We, and others, have previously shown that a conserved C-terminal polyproline motif in NS5A interacts with the SH3 domains of a range of cellular proteins. Although the functional consequences of these interactions remain to be elucidated, recent evidence suggests that this motif may be important for virus replication , and thus represents a valid target for antiviral drug development. We therefore performed a detailed biochemical and biophysical analysis of the interaction between NS5A and SH3 domains. To facilitate this analysis we expressed two N-terminally deleted forms of NS5A in E. coli – firstly NS5A(Δ32), in which the membrane anchoring amphipathic helix was removed to aid solubility . Secondly, as we had previously shown that the N-terminal 270 residues were dispensable for SH3 domain binding (Andrew Macdonald, PhD thesis, University of Leeds), we expressed NS5A(Δ250) in which both the amphipathic helix and domain I  were deleted. Both proteins were expressed with an N-terminal hexahistidine tag to aid purification. Figure 1a shows a schematic of the expressed proteins and figure 1b western blot analysis and Coomassie Blue staining of various stages in the purification process. We established a two stage purification protocol in which NS5A was first purified via the hexahistidine tag by immobilised metal affinity chromatography and further purified by gel filtration (lanes 10). Using this protocol, both forms of NS5A could be purified to approximately 80% purity as judged by Coomassie blue staining (lanes 11). The two forms of NS5A migrated on SDS-PAGE with apparent molecular masses of 55 kDa (Δ32) and 40 kDa (Δ250). To confirm that the expressed proteins were the correct molecular mass they were subjected to slow crystallisation mass spectrometry , figure 1c demonstrates that the actual molecular masses were in close agreement with predicted masses. Of note, the apparent molecular masses of each NS5A derived protein species (as indicated by the aberrant migration of the protein on SDS-PAGE) were significantly higher than the actual molecular masses, this is most likely due to the high proline content of NS5A (11% in the intact protein).
We had previously shown that NS5A bound to the SH3 domain of the Fyn tyrosine kinase and that in the context of the intact kinase this interaction led to Fyn activation. As Fyn is expressed in Huh7 cells  that are permissive for HCV replication we chose to use the Fyn SH3 domain as a basis for our investigation. We first confirmed that the bacterially expressed NS5A was able to bind a GST-Fyn SH3 domain fusion protein in vitro (figure 1d), in agreement with our previous data both forms of NS5A (Δ32 and Δ250) bound equally well. This observation also demonstrated that eucaryotic post-translational modifications were not required for the NS5A-SH3 domain interaction.
Kinetic parameters for the NS5A:Fyn SH3 domain interaction.
4.93 × 103
3.08 × 10-3
6.29 × 10-7
(± SD) n = 3
(± 0.66 × 103)
(± 0.16 × 10-3)
(0.59 × 10-7)
9.05 × 103
4.94 × 10-3
5.56 × 10-7
(± SD) n = 3
(± 1.62 × 103)
(± 0.11 × 10-3)
(0.59 × 10-7)
Interestingly, of the nine residues predicted to contribute to the binding energy of the interaction, eight were conserved between Fyn and c-Src (the only difference being D99 in the RT-loop – altered to T99 in c-Src). Despite this both we  and others  had previously observed that NS5A was unable to bind to the SH3 domain of Src so to determine if other residues in the SH3 domain might make a contribution to the interaction we proceeded to make a second set of mutations. In order to avoid any potential structural effects we chose to mutate four residues in Fyn to their corresponding c-Src residues. Three of these were non-conservative changes: A95S, E121L and E129Q, the fourth was a conservative change, L112V. We therefore made the corresponding mutations within the Fyn SH3 domain, expressed them as GST-fusion proteins and tested these mutant proteins for binding to NS5A by ELISA (figure 4b). None of these mutations had any significant effect on the binding to NS5A.
Our data are consistent with the notion that the PP2.2 polyproline motif of NS5A is a promiscuous and high affinity SH3 ligand, able to mediate binding of NS5A to a wide range of SH3 domains. The binding of NS5A to the Fyn SH3 domain is remarkably resistant to single or multiple amino acid substitutions, apart from the relatively well conserved residues – tyrosines 91 and 93 and tryptophan 119 – mutation of which reduced binding to background levels. These three residues have previously been shown to play critical roles in peptide binding and are highly conserved , thus the dramatic effect on NS5A binding is in line with expectations. The affinity of NS5A for the Fyn SH3 domain is higher than the corresponding values for most cellular SH3 domains interacting with their cognate ligands – generally such interactions have calculated KD between 1–50 μM , although some have been reported to have much higher affinities, eg the amphiphysin:dynamin I interaction was measured at 190 nM . The comparison of binding affinities suggests that NS5A would be able to effectively compete with cellular ligands for binding to SH3 domains. In this context it will be of great interest to determine which SH3 domain containing proteins interact with NS5A in cells infected with HCV, such experiments are ongoing in our laboratory. It is interesting to note that a recent study  pointed to a key role for Fyn in HCV RNA replication. However, in apparent contrast to our previous data demonstrating activation of Fyn by NS5A, this study showed that Fyn activation via phosphorylation mediated by the upstream kinase, Csk, resulted in inhibition of replicon replication.
Protein expression and purification
Coding sequences for the two N-terminally truncated forms of NS5A were amplified by PCR using the J4 genotype 1b clone of HCV  as template and cloned into pET14b. Primer sequences are available upon request. Protein expression was carried out in E. coli BL21 pLysS (DE3). Briefly, a single colony was grown in LB containing 100 μg/ml ampicillin, 50 μg/ml chloramphenicol and 1% (w/v) glucose at 37°C until OD600 = 0.6. The culture was chilled at 4°C for 30 minutes prior to induction with 0.2 mM IPTG at 27°C for 5 hours. Bacterial pellets were resuspended in buffer A (20 mM disodium orthophosphate, pH 7.5, 0.5 M NaCl, 5 mM MgCl2), containing 1 mg/ml lysozyme, 2 μg/ml DNase, 1 μg/ml RNase, 0.5% Triton X-100 and EDTA-free complete protease inhibitor cocktail (Roche), sonicated, clarified by centrifugation (16,000 × g at 4°C for 1 hour) and applied to a Ni2+-charged NTA-sepharose column. The column was washed extensively in buffer A containing 20 mM imidazole and eluted in the same buffer containing 300 mM imidazole and 0.1% Triton X-100. NS5A-containing fractions were pooled, dialysed overnight against HBS buffer, clarified by centrifugation and injected onto an Amersham XK 16/70 size exclusion column packed with Superdex75 (Amersham Biosciences). Fractions containing intact protein were again pooled and stored at -80°C until use. GST-SH3 domain fusion proteins were expressed and purified as previously described .
GST pulldown assay
GST-SH3 domain fusion proteins were bound to glutathione agarose (GA)-beads at 4°C for 1 h. 5 μg of purified NS5A protein was applied to the beads and incubated at 4°C on a blood mixer for 3 hours. The beads were washed twice in GLB (10 mM PIPES-NaOH pH 7.2, 120 mM KCl, 30 mM NaCl, 5 mM MgCl2, 1% (v/v) Triton X-100, 10% (v/v) glycerol) supplemented with 0.5 M KCl, and three times in GLB only. Bound proteins were eluted from the GA-beads by incubating in the presence of 20 mM reduced glutathione in GLB. Samples were analysed by western blot and Coomassie stained SDS-PAGE to confirm equal GST-SH3 domain fusion protein loading onto the GA-beads.
1 μg/well of either GST or the appropriate GST-SH3 domain fusion proteins in 50 μl of PBS was coated on Greiner bio-One PS 96-well microplates overnight at 4°C. Wells were rinsed with PBS/0.1% (v/v) Tween-20 (PBS-T) and blocked in PBS-T containing 5% (w/v) dried semi-skimmed milk powder (PBS-TM) for 2 hours at room temperature. After washing in PBS-T, 0.5 μg/well of purified NS5A was added in 50 μl of PBS-T and incubated for 2 hours at 4°C. Bound NS5A was detected with a sheep polyclonal anti-NS5A sera (1:5000 dilution) in PBS-TM followed by donkey anti-sheep-HRP (Sigma). The ELISA was developed using OPD, the reaction was stopped with 0.5 M sulphuric acid. The ELISA plate was read at 490 nm (referenced at 630 nm) using an MRX plate reader (Dynex). All samples were run in triplicate and an average taken in each case. To control for differential binding of the GST-SH3 domains to the 96-well microplate, a GST loading ELISA was utilised. In this case the primary antibody was a mouse anti-GST mAb (Serotec), and the secondary was a goat anti-mouse HRP conjugate (Sigma). The amount of relative binding for each GST-SH3 fusion protein was analysed and the signal from the NS5A ELISA normalised appropriately.
Surface Plasmon Resonance
Experiments were carried out on a Biacore 3000 in HBS buffer (10 mM Hepes-NaOH pH 7.4, 150 mM NaCl, 0.005% Tween-20) at 25°C. An anti-GST antibody (Biacore) was amine coupled to a CM5 sensor chip which allowed the capture and immobilisation of 2 μg of purified GST-SH3 domains in a uniform orientation to generate a binding surface. A reference surface containing antibody only was also prepared. Eight concentrations of purified NS5A(Δ32) or NS5A(Δ250) (3 μM – 100 nM), were injected across the binding or reference sensor chip surface at 30 μl/minute for 8 minutes followed by 8 minutes dissociation, in triplicate. A corrected binding profile was then generated by subtraction of the reference signal from the binding signal for each concentration. A 1:1 Langmuir binding curve was applied to the concentration series of each protein and the association (ka), dissociation (kd) rates and affinity constant (KD) were calculated.
hepatitis C virus
non-structural 5A protein
Src homology 3.
We thank Kalle Saksela (University of Helsinki) for reagents, Andy Baron and Peter Stockley (University of Leeds) for advice with SPR experiments and Andrew Macdonald (University of Leeds) for critical reading of this manuscript. HS was the recipient of a Biomolecular Sciences Committee PhD studentship from the Biotechnology and Biological Sciences Research Council. Research in the MH laboratory is supported by the Wellcome Trust, Medical Research Council and Yorkshire Cancer Research.
- Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4View ArticlePubMed
- Macdonald A, Harris M: Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004, 85: 2485-2502. 10.1099/vir.0.80204-0View ArticlePubMed
- Brass V, Bieck E, Montserret R, Wolk B, Hellings JA, Blum HE, Penin F, Moradpour D: An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 2002, 277: 8130-8139. 10.1074/jbc.M111289200View ArticlePubMed
- Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM: The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004, 279: 48576-48587. 10.1074/jbc.M407787200View ArticlePubMed
- Tellinghuisen TL, Marcotrigiano J, Rice CM: Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005, 435: 374-379. 10.1038/nature03580PubMed CentralView ArticlePubMed
- Macdonald A, Crowder K, Street A, McCormick C, Harris M: The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol 2004, 85: 721-729. 10.1099/vir.0.19691-0View ArticlePubMed
- Tan SL, Nakao H, He YP, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG: NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999, 96: 5533-5538. 10.1073/pnas.96.10.5533PubMed CentralView ArticlePubMed
- Zech B, Kurtenbach A, Krieger N, Strand D, Blencke S, Morbitzer M, Salassidis K, Cotten M, Wissing J, Obert S, Bartenschlager R, Herget T, Daub H: Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. J Gen Virol 2003, 84: 555-560. 10.1099/vir.0.18801-0View ArticlePubMed
- Nanda SK, Herion D, Liang TJ: Src homology 3 domain of hepatitis C virus NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology 2006, 130: 794-809. 10.1053/j.gastro.2005.12.030View ArticlePubMed
- Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M: The hepatitis C virus NS5A protein inhibits activating protein-1 (AP1) function by perturbing Ras-ERK pathway signalling. J Biol Chem 2003, 278: 17775-17784. 10.1074/jbc.M210900200View ArticlePubMed
- Macdonald A, Mazaleyrat S, McCormick C, Street A, Burgoyne NJ, Jackson RM, Cazeaux V, Shelton H, Saksela K, Harris M: Further studies on hepatitis C virus NS5A-SH3 domain interactions: identification of residues critical for binding and implications for viral RNA replication and modulation of cell signalling. J Gen Virol 2005, 86: 1035-1044. 10.1099/vir.0.80734-0View ArticlePubMed
- Lee CH, Leung B, Lemmon MA, Zheng J, Cowburn D, Kuriyan J, Saksela K: A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J 1995, 14: 5006-5015.PubMed CentralPubMed
- Hanna Z, Weng XD, Kay DG, Poudrier J, Lowell C, Jolicoeur P: The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J Virol 2001, 75: 9378-9392. 10.1128/JVI.75.19.9378-9392.2001PubMed CentralView ArticlePubMed
- Arold S, Franken P, Strub MP, Hoh F, Benichou S, Benarous R, Dumas C: The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 1997, 5: 1361-1372. 10.1016/S0969-2126(97)00286-4View ArticlePubMed
- Huang L, Sineva EV, Hargittai MR, Sharma SD, Suthar M, Raney KD, Cameron CE: Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli. Protein Expr Purif 2004, 37: 144-153. 10.1016/j.pep.2004.05.005View ArticlePubMed
- Clarke D, Griffin S, Beales L, Gelais CS, Burgess S, Harris M, Rowlands D: Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J Biol Chem 2006, 281: 37057-37068. 10.1074/jbc.M602434200View ArticlePubMed
- Larson SM, Davidson AR: The identification of conserved interactions within the SH3 domain by alignment of sequences and structures. Protein Sci 2000, 9: 2170-2180.PubMed CentralView ArticlePubMed
- Grabs D, Slepnev VI, Songyang Z, David C, Lynch M, Cantley LC, De Camilli P: The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence. J Biol Chem 1997, 272: 13419-13425. 10.1074/jbc.272.20.13419View ArticlePubMed
- Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A, Schultz PG: Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008, 283: 29-36. 10.1074/jbc.M703988200View ArticlePubMed
- Yanagi M, StClaire M, Shapiro M, Emerson SU, Purcell RH, Bukh J: Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo . Virology 1998, 244: 161-172. 10.1006/viro.1998.9092View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.